Li Zheng

National Medical Products Administration Key Laboratory For Clinical Research And Evaluation Of Innovative Drugs
Chengdu, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study.

Safety and preliminary efficacy results of IBI389, an anti-Claudin18.2×CD3 bispecific antibody, in patients with solid tumors and gastric or gastro-esophageal tumors: a phase 1 dose escalation and expansion study.

Journal: BMC medicine

Published: July 30, 2025

Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor-Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations.

Successful Pregnancy and Healthy Baby Outcome in a Patient With Tyrosine Kinase Inhibitor-Refractory ALK-Positive NSCLC and Central Nervous System Metastasis Treated With Lorlatinib With Maternal-Fetal Pharmacokinetics and Child Milestone Development Correlations.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: April 29, 2025

Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors.

Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors.

Journal: Signal transduction and targeted therapy

Published: November 17, 2024

Safety, tolerability, and pharmacokinetic of HY0721 in Chinese healthy subjects: A first-in-human randomized, double-blind, placebo-controlled dose escalation phase I study.

Safety, tolerability, and pharmacokinetic of HY0721 in Chinese healthy subjects: A first-in-human randomized, double-blind, placebo-controlled dose escalation phase I study.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: February 06, 2024

First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects.

First-in-human safety, tolerability, and pharmacokinetics of SY-007, a prolonged action neuroprotective drug for ischemic stroke, in healthy Chinese subjects.

Journal: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences

Published: August 29, 2021

Development and validation of a UPLC-MS/MS method for quantification of C-005, a novel third-generation EGFR TKI, and its major metabolite in plasma: Application to its first-in-patient study.

Development and validation of a UPLC-MS/MS method for quantification of C-005, a novel third-generation EGFR TKI, and its major metabolite in plasma: Application to its first-in-patient study.

Journal: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Published: September 02, 2020

Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO-R Agonist, in Healthy Individuals.

Safety, Pharmacokinetics and Pharmacodynamics of Hetrombopag Olamine, a Novel TPO-R Agonist, in Healthy Individuals.

Journal: Basic & clinical pharmacology & toxicology

Published: March 07, 2017

A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.

A pharmacokinetic and pharmacodynamic comparison of a novel pegylated recombinant consensus interferon-α variant with peginterferon-α-2a in healthy subjects.

Journal: British journal of clinical pharmacology

Published: April 06, 2014

Showing 1-8 of 8

Last Updated: 09/26/2026